Finland’s Palko (Cohere) has started a new recommendation process in mantle cell lymphoma.
What happened
Palko (the council for choices in health care) has started preparing a recommendation on lisocabtagene maraleucel (Breyanzi) for the treatment of mantle cell lymphoma.
Process and evidence base
-
The recommendation is part of an indication expansion pilot.
-
The information base for the recommendation draws on a Fimea assessment statement completed in April 2026.
Planned timeline and consultations
-
A draft recommendation is expected in autumn 2026 and will be published for comments in the otakantaa.fi service.
-
The final recommendation is planned for later in autumn 2026.
-
Palko is also inviting early input during the preparation phase: comments can be sent by 15 May 2026.
